摘要
为探讨重组人生长激素对肝硬化低蛋白血症的临床治疗作用及特点 ,将 5 4例血清白蛋白含量低于 3 5 g·L-1的肝硬化低蛋白血症患者随机分为 3组 :重组人生长激素治疗组 (A)给予重组人生长激素 4IU ,肌注 ,1次 /2日 ,疗程 3 0d ,人血白蛋白治疗组(B)给予 2 0 %人血白蛋白 10 0g ,静滴 ,2次 /周 ,疗程 3 0d ,两组给予相同保肝、对症药物治疗方案 ,对照组 (C)只给予相同方案的保肝、对症治疗药物。分别于开始治疗后 15、3 0、60、90d测定各项观察指标。治疗后 15天白蛋白治疗组血清白蛋白含量上升 (P <0 0 5 ) ,3 0d时 3组患者血清白蛋白含量均上升 (P <0 .0 5 ) ,两组治疗组上升更明显 ;60d后生长激素治疗组血清白蛋白水平升至高点水平 ,白蛋白治疗组及对照组较前降低 ,组间差异显著 (P <0 .0 1) ;90d后生长激素治疗组血清白蛋白含量仍维持高点水平 ,且肝功能好转 ,而白蛋白治疗组及对照组降至治疗前水平 ,提示重组人生长激素可明显提高肝硬化低蛋白血症患者血清白蛋白水平 ,改善肝功能 ,中远期疗效好。
Objective:To investigate the effect of human growth hormone in the treatment of liver cirrhosis with hypoproteinemia. Methods:Fifty four patients with liver cirrhosis,whose albumin level was below 35 g·L -1 ,were randomly divided into three groups: recombinant human growth hormone treatment group(Group A), albumin treatment group(Gruop B) and control group.Contents of albumin,ALT and other items were measured 15,30,60 and 90 day after the treatments. Results: An increase in plasma albumin content was observed in groupB 15 days after the treatment( P< 0.05), and in all groups 30 days after( P <0.05),but the change in the control group was not so significant as that in both treatment groups. 60 days after the treatments,the plasma albumin in Group A reached the peak level,but it dropped in group B and the control group ( P <0.01).90 days after the treatments,the plasma albumin remained at a higher level in Group A but dropped to the level as before treatments in Group B and the control group. Conclusion: This results showed that the recombinant human growth hormone can increase the level of albumin and improve the liver function in patients with liver cirrhosis with a long term curative effect.
出处
《广东药学院学报》
CAS
2002年第2期148-151,共4页
Academic Journal of Guangdong College of Pharmacy
